S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01

Axcella Health Stock Forecast, Price & News

-0.06 (-3.19%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
64,100 shs
Average Volume
59,900 shs
Market Capitalization
$70.83 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AXLA News and Ratings via Email

Sign-up to receive the latest news and ratings for Axcella Health and its competitors with MarketBeat's FREE daily newsletter.

Axcella Health logo

About Axcella Health

Axcella Health, Inc. is a biotechnology company. It engages in the research and development of treatment for diseases and improve health using endogenous metabolic modulator, or EMM, and compositions. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy; and AXA1125, for non-alcoholic steatohepatitis. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$2.01 per share


Net Income
$-56.53 million
Pretax Margin




Free Float
Market Cap
$70.83 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.18 out of 5 stars

Medical Sector

410th out of 1,405 stocks

Biological Products, Except Diagnostic Industry

65th out of 202 stocks

Analyst Opinion: 3.3Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Axcella Health (NASDAQ:AXLA) Frequently Asked Questions

Is Axcella Health a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Axcella Health in the last twelve months. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Axcella Health stock.
View analyst ratings for Axcella Health
or view top-rated stocks.

How has Axcella Health's stock been impacted by COVID-19 (Coronavirus)?

Axcella Health's stock was trading at $3.32 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AXLA shares have decreased by 45.2% and is now trading at $1.82.
View which stocks have been most impacted by COVID-19

When is Axcella Health's next earnings date?

Axcella Health is scheduled to release its next quarterly earnings announcement on Wednesday, March 16th 2022.
View our earnings forecast for Axcella Health

How were Axcella Health's earnings last quarter?

Axcella Health Inc. (NASDAQ:AXLA) announced its earnings results on Wednesday, November, 10th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.04.
View Axcella Health's earnings history

What price target have analysts set for AXLA?

8 brokerages have issued 1 year price targets for Axcella Health's shares. Their forecasts range from $5.00 to $14.00. On average, they anticipate Axcella Health's stock price to reach $9.67 in the next year. This suggests a possible upside of 431.1% from the stock's current price.
View analysts' price targets for Axcella Health
or view top-rated stocks among Wall Street analysts.

Who are Axcella Health's key executives?

Axcella Health's management team includes the following people:
  • William R. Hinshaw, President, Chief Executive Officer & Director
  • Tony Tramontin, Chief Scientific Officer, Senior VP-R&D
  • Margaret Koziel, Chief Medical Officer & Senior Vice President
  • Alison Schecter, President-Research & Development
  • Paul Fehlner, Secretary, Chief Legal Officer & Senior VP

What is Bill Hinshaw's approval rating as Axcella Health's CEO?

3 employees have rated Axcella Health CEO Bill Hinshaw on Glassdoor.com. Bill Hinshaw has an approval rating of 100% among Axcella Health's employees. This puts Bill Hinshaw in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Axcella Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axcella Health investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Evofem Biosciences (EVFM), ADMA Biologics (ADMA), Coty (COTY), Energy Transfer (ET), Myovant Sciences (MYOV), NVIDIA (NVDA), Pfizer (PFE) and Moderna (MRNA).

When did Axcella Health IPO?

(AXLA) raised $76 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 3,600,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and SVB Leerink served as the underwriters for the IPO.

What is Axcella Health's stock symbol?

Axcella Health trades on the NASDAQ under the ticker symbol "AXLA."

How do I buy shares of Axcella Health?

Shares of AXLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axcella Health's stock price today?

One share of AXLA stock can currently be purchased for approximately $1.82.

How much money does Axcella Health make?

Axcella Health has a market capitalization of $70.83 million. The company earns $-56.53 million in net income (profit) each year or ($1.63) on an earnings per share basis.

How many employees does Axcella Health have?

Axcella Health employs 59 workers across the globe.

What is Axcella Health's official website?

The official website for Axcella Health is www.axcellahealth.com.

Where are Axcella Health's headquarters?

Axcella Health is headquartered at 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139.

How can I contact Axcella Health?

Axcella Health's mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at (857) 320-2200, via email at [email protected], or via fax at 617-441-6243.

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.